Drug Shortage Report for BEXSERO
Report ID | 63383 |
Drug Identification Number | 02417030 |
Brand name | BEXSERO |
Common or Proper name | Multicomponent Meningococcal B Vaccine (recombinant, adsorbed) |
Company Name | GLAXOSMITHKLINE INC |
Market Status | MARKETED |
Active Ingredient(s) | Recombinant Neisseria meningitidis group B NHBA fusion protein Recombinant Neisseria meningitidis group B NadA protein Recombinant Neisseria meningitidis group B fHBP fusion protein Outer membrane vesicles |
Strength(s) | 50MCG 50MCG 50MCG 25MCG |
Dosage form(s) | SUSPENSION |
Route of administration | INTRAMUSCULAR |
Packaging size | 1's |
ATC code | J07AH |
ATC description | BACTERIAL VACCINES |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | |
Actual start date | 2018-10-01 |
Estimated end date | 2018-12-06 |
Actual end date | 2018-10-29 |
Shortage status | Resolved |
Updated date | 2018-10-31 |
Company comments | Supply disruptions may be seen in the private market for packages of 1. Product under allocation. BEXSERO is available in packages of 10. |
Health Canada comments | |
Tier 3 Status | No |
Company contact information | 1-800-387-7374 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2018-10-31 | French | Compare |
v5 | 2018-10-31 | English | Compare |
v4 | 2018-10-26 | French | Compare |
v3 | 2018-10-26 | English | Compare |
v2 | 2018-10-05 | French | Compare |
v1 | 2018-10-05 | English | Compare |
Showing 1 to 6 of 6